Table 2. Multivariate Cox analysis for 5-year DFS and BCSS in the derivation and validation cohorts.
| Hazard ratio (CI) | Significance | |
|---|---|---|
|
Derivation cohort | ||
| 5-year DFS | ||
| Lymph node | 1.895 (1.453–2.472) | P=0.00005 |
| Grade | 1.560 (1.001–2.431) | P=0.050 |
| Size | 1.380 (0.918–2.173) | P=0.121 |
| CERneg | 4.441 (1.895–10.411) | P=0.001 |
| CERimp | 2.869 (1.240–6.639) | P=0.014 |
| HER2+ | 1.676 (1.004–2.798) | P=0.048 |
| BCSS | ||
| Lymph node | 1.833 (1.428–2.353) | P=0.000002 |
| Grade | 1.504 (1.026–2.203) | P=0.036 |
| Size | 1.711 (1.196–2.448) | P=0.003 |
| CERneg | 2.024 (1.065–3.848) | P=0.031 |
| CERimp | 1.788 (0.974–3.283) | P=0.061 |
| HER2+ | 1.182 (0.717–1.948) | P=0.511 |
| 5-year DFS in ER+ patients | ||
| Lymph node | 2.027 (1.281–3.209) | P=0.003 |
| Grade | 1.646 (0.899–3.012) | P=0.106 |
| Size | 1.208 (0.639–2.35) | P=0.561 |
| CERimp | 2.469 (1.049–5.810) | P=0.038 |
| PRneg | 0.956 (0.409–2.236) | P=0.917 |
| HER2+ | 4.160 (1.803–9.603) | P=0.001 |
| BCSS ER+ patients | ||
| Lymph node | 2.070 (1.406–3.049) | P=0.0002 |
| Grade | 1.825 (1.167–2.855) | P=0.008 |
| Size | 1.723 (1.167–2.806) | P=0.029 |
| CERimp | 1.946 (1.054–3.596) | P=0.033 |
| PRneg | 0.928 (0.464–1.858) | P=0.833 |
| HER2+ | 1.535 (0.644–3.629) | P=0.329 |
|
Validation cohort | ||
| DFS | ||
| Lymph node | 1.818 (1.282–2.579) | P=0.001 |
| Grade | 1.266 (0.731–2.192) | P=0.400 |
| Size | 1.416 (0.825–2.428) | P=0.207 |
| CERneg | 5.722 (2.727–12.003) | P=0.000004 |
| CERimp | 2.431 (1.196–4.941) | P=0.014 |
| DFS in ER+ patients | ||
| Lymph node | 2.388 (1.554–3.671) | P=0.00007 |
| Grade | 1.445 (0.805–2.594) | P=0.218 |
| Size | 1.299 (0.680–2.480) | P=0.428 |
| CERimp | 2.096 (1.010–4.351) | P=0.047 |
| PRneg | 0.763 (0.299–1.948) | P=0.571 |
Abbreviations: BCSS=breast cancer-specific survival; CER=combined endocrine receptor; CI=confidence interval; DFS=disease-free survival; ER=oestrogen receptor; HER2+=human epidermal growth factor receptor 2-positive; imp=impaired; neg=negative; PR=progesterone receptor.